Butyrate-Producing Clostridium butyricum: A Direct Interactor with Colorectal Cancer Cells that Reverses Immune Suppression and Enhances Checkpoint Inhibitor Efficacy
Posted inClinical Updates Family Medicine & Nutrition Gastroenterology news Oncology Specialties

Butyrate-Producing Clostridium butyricum: A Direct Interactor with Colorectal Cancer Cells that Reverses Immune Suppression and Enhances Checkpoint Inhibitor Efficacy

Recent research uncovers that the probiotic Clostridium butyricum directly interacts with colorectal cancer cells to inhibit immune suppression via the secD-GRP78 axis, restoring CD8+ T cell antitumor function and enhancing PD-1 inhibitor therapy.
Advancing Radiotherapy in High-Grade Glioma: Targeted Volume Reduction with Hypofractionated Simultaneous Boost IMRT
Posted inClinical Updates Oncology Radiology Specialties

Advancing Radiotherapy in High-Grade Glioma: Targeted Volume Reduction with Hypofractionated Simultaneous Boost IMRT

A randomized trial demonstrates that modified target delineation integrating multimodal MRI and white matter tractography with moderately hypofractionated radiotherapy achieves comparable survival outcomes to standard IMRT while reducing irradiation volumes in high-grade glioma patients.
Comparative Efficacy of Induction-Concurrent Versus Concurrent-Adjuvant Chemoradiotherapy in High-Risk N2-N3 Nasopharyngeal Carcinoma: Insights from a Phase 3 Randomized Trial
Posted inOncology Radiology Specialties

Comparative Efficacy of Induction-Concurrent Versus Concurrent-Adjuvant Chemoradiotherapy in High-Risk N2-N3 Nasopharyngeal Carcinoma: Insights from a Phase 3 Randomized Trial

A phase 3 trial showed no significant difference in 3-year progression-free survival between induction-concurrent and concurrent-adjuvant chemoradiotherapy in treating high-risk N2-N3 nasopharyngeal carcinoma, with both regimens exhibiting manageable safety profiles.
Mupirocin Nasal Ointment Significantly Reduces Severe Acute Radiation Oral Mucositis in Nasopharyngeal Cancer Patients: Insights from a Phase 3 Trial
Posted inOncology Radiology Specialties

Mupirocin Nasal Ointment Significantly Reduces Severe Acute Radiation Oral Mucositis in Nasopharyngeal Cancer Patients: Insights from a Phase 3 Trial

A phase 3 trial demonstrates that mupirocin nasal ointment used for bacterial decolonization effectively lowers severe acute radiation oral mucositis rates, improves quality of life, and reduces Staphylococcus aureus colonization in nasopharyngeal cancer patients undergoing radiotherapy.